CS
RNAM

Credit Suisse’s Avidity Biosciences RNAM Stock Holding History

Credit Suisse’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.7M Buy
66,776
+16,448
+33% +$258K ﹤0.01% 1965
2023
Q4 		$455K Sell
50,328
-5,795
-10% -$38.7K ﹤0.01% 2773
2023
Q3 		$358K Sell
56,123
-24,866
-31% -$214K ﹤0.01% 2862
2023
Q2 		$898K Buy
80,989
+32,807
+68% +$412K ﹤0.01% 2452
2023
Q1 		$740K Buy
48,182
+5,193
+12% +$114K ﹤0.01% 2509
2022
Q4 		$954K Buy
42,989
+12,555
+41% +$187K ﹤0.01% 2373
2022
Q3 		$497K Buy
30,434
+5,647
+23% +$108K ﹤0.01% 2779
2022
Q2 		$360K Sell
24,787
-1,868
-7% -$27.8K ﹤0.01% 3052
2022
Q1 		$492K Buy
26,655
+36
+0.1% +$612 ﹤0.01% 2981
2021
Q4 		$633K Buy
26,619
+3,361
+14% +$80.3K ﹤0.01% 3651
2021
Q3 		$572K Buy
+23,258
New +$506K ﹤0.01% 3720
2021
Q2 		– Sell
-10,784
Closed -$235K – 4587
2021
Q1 		$235K Sell
10,784
-14,396
-57% -$352K ﹤0.01% 4079
2020
Q4 		$642K Buy
+25,180
New +$734K ﹤0.01% 3652

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse's RNAM Position: Q1 2024 in Review

Credit Suisse increased its Avidity Biosciences (RNAM) stake by 33% in Q1 2024, buying an estimated $258K and bringing the position to 66,776 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Credit Suisse first reported a position in RNAM in Q4 2020 and has held it in 13 quarters since. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • Credit Suisse held 66,776 shares of Avidity Biosciences worth $1.7M as of Q1 2024.
  • Credit Suisse bought 16,448 Avidity Biosciences shares in Q1 2024, an estimated $258K.
  • Avidity Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1965 holding.
  • Credit Suisse first reported a position in Avidity Biosciences in Q4 2020 and has held it in 13 quarters since.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.